Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Cullinan Therapeutics reports Q1 2026 financials showing a net loss of $49.7 million with cash runway into 2029. The company highlights the FDA acceptance of the NDA for zipalertinib in relapsed EGFR ex20ins NSCLC with a PDUFA date set for February 27, 2027. Clinical data presentations for its T cell engager pipeline in autoimmune diseases and onco…